Purpose: Estimating the rate of adverse events (AEs) caused by a treatment in clinical trials typically involves comparing the proportions of patients experiencing AEs in intervention and control groups. However, potentially important information, including duration, recurrence, and intensity of events, is lost. In this study, we illustrate how the additional information can be obtained and incorporated into analyses of AEs.
In 2007, Japan banned oseltamivir use in teenagers because of observed abnormal behaviour causing accidental deaths in those administered the drug. 2 In 2008, the manufacturer reviewed oseltamivir's safety, reporting that significantly fewer patients randomised to the drug (12/1662; 0.7%) had neuropsychiatric AEs compared to placebo (20/1128; 1.8%; P < .05) in prophylaxis trials, citing "data on file". 3 2 | METHODS
| Selection of studies
We included all prophylaxis randomised studies of oseltamivir compared to placebo where a CSR was available, using prophylactic trials because of their increased patient surveillance time and because the psychiatric AEs reported were less likely to be attributed to influenza-like illness when patients were influenza free at baseline ( Adverse events were defined in the clinical trials as any change from the patient's baseline condition which occurred during the trial after treatment began irrespective of whether it was thought to be related to the study treatment. Symptoms of influenza were not counted as AEs unless they fulfilled the criteria for serious AEs. Exact timing on when information was obtained from patients on AEs throughout the follow-up period differed between studies (Table 1) .
Information on AEs was obtained via patient interview and recorded onto standardised AE case report forms. Any unresolved AEs at the end of the study were followed up until they were either resolved or until an explanation was obtained as to why no end date was available.
Further detail on the information collected on AEs for each clinical trial is available in the blank case report forms contained in module 2 of the CSRs (see complete data, referenced above, for access).
| Statistical methods
We compared the proportion of days patients suffered from psychiatric AEs between trial groups. For example, a patient with depression for 10 days and subsequently anxiety for 5 days over the 8 week followup would have 15/56-day suffering from psychiatric AEs. This accounts for multiple AEs, as well as their duration, which is not possible if a simple dichotomy between proportions of patients affected is used.
We analysed the data using single stage individual patient metaanalysis via logistic regression models. 13 Differences in AE rates between trials (possibly due to differences in baseline demographics such as age or differences in follow-up duration) were accounted for by including a categorical variable in the models indicating each trial data, and a variable in the model tested the interaction between trial and treatment group on the outcome. Intensity of the AE was incorporated into a second analysis by using weighted nominal logistic
KEY POINTS
• There has been much scientific debate on whether oseltamivir plays a causal role in the development of psychiatric adverse events.
• Using detailed previously unavailable data obtained from clinical study reports of prophylaxis trials and novel statistical and graphical methods, we show evidence of a causal effect of oseltamivir on psychiatric adverse events.
• The increase in absolute risk of experiencing a psychiatric adverse event is small.
• We believe that our methods can be used more generally to provide new insights into the unintended effects of pharmaceutical interventions.
regression, with weights and outcome based on the number of days the patient suffered from each of severe, moderate, mild, and no psychiatric AE. As the unit of analysis was days within patients, we estimated cluster robust standard errors to account for repeated measures where each patient was a cluster.
Percentages of days affected by psychiatric AEs by intensity were estimated from predicted probabilities obtained from the weighted nominal logistic regression model. We also estimated number of patient days of treatment that would lead to 1 additional day of suffering from a psychiatric AE of any intensity. We did this by subtracting the estimated proportion of days affected by psychiatric AEs in the placebo group from that of the treatment group and then taking the reciprocal of this value. We also made an adjustment to account for most patients being treated for 6 weeks but followed up for a further 2 weeks. In addition to the statistical analysis, we present plots of the psychiatric AEs over the follow-up of the studies for individual patients.
For each patient with an event, a horizontal line segment shows day of initiation as well as duration of the event. Intensity is illustrated using different line styles, and events unresolved at the end of the follow-up are indicated using hollow circles. Multiple events within patients can be shown using multiple line segments, and numbers of patients with events are shown on the y-axis. Plots are stratified by treatment group with numbers of patients contributing to safety assessment provided next to the treatment group labels.
| RESULTS
Adverse effects in the treatment group were more frequent and severe, of longer duration, and possibly of earlier occurrence, than in the placebo group in the 3 prophylaxis trials of 6 weeks of treatment with oseltamivir for individuals exposed to influenza (Figures 1 and 2) .
A postexposure prophylaxis trial, WV15799, where exposure to medication was for only 7 days, had few events (Figure 3 ). There were 13 One patient classified as having severe hallucinations in the oseltamivir group of study WV15825 was also classified as having severe depression and severe confusion simultaneously. For the purposes of our analysis, this was considered to be 1 psychiatric event.
types of AEs reported in the 4 clinical trials (classified by MedDRA preferred terms) ( Table 2 ).
The proportion of days patients suffered from a psychiatric AE was greater in oseltamivir groups, odds ratio ( (Table 3 ).
In the additional analysis of trial WV15673/97, there was insufficient evidence of a dose-response effect of oseltamivir on proportion of days patients suffered from a psychiatric AE, OR 1.30 (95% CI 0.74 to 2.27).
| DISCUSSION
We found that patients using oseltamivir had a greater than threefold increased odds of suffering from a psychiatric AE compared to those using placebo, most notably for events with severe intensity, suggesting a causal effect. Although the relative effect is very high for severe events, the absolute increase is small when considered in the context of all patients included in the study over the 3 to 8-week follow-up periods. The effect was consistent over the 3 trials where exposure to treatment was 6 weeks long, but not for the 1 study, where exposure was for only 1 week, perhaps because of the reduced exposure, reduced follow-up, or insufficient power to discern enough AEs. There was insufficient evidence of a doseresponse effect of treatment on odds of suffering from a psychiatric AE; however, this analysis was only able to be performed using 1 trial; hence, power is low.
One important limitation of this research is that children were not included in any of the trials (despite oseltamivir being approved by the 14 Perhaps even more important than these findings specific to oseltamivir is our use of novel methods based on using CSRs.
Obtaining access to these documents has allowed us to conduct very detailed analyses far beyond what is possible with conventional published trials, allowing us to incorporate important information only available in the CSRs, including multiple events suffered by individual patients, duration of events, and the intensity of events. Some of the data used for this study had been previously extracted from
CSRs for a systematic review of neuraminidase inhibitors. 5 Data extraction was somewhat labour intensive; however, CSRs are required to conform to a reporting standard, 15 and the oseltamivir CSRs were relatively easy to navigate around once familiarity of the format had been attained. In future work, we plan to investigate whether AE data from CSRs can be converted from pdf format to electronic spreadsheet format to facilitate full analysis of all AE data contained in CSRs.
This study illustrates the importance of transparency of clinical trial data. Transparency can be improved with public access to clinical study reports. This has already occurred to some degree with the EMA releasing CSRs to independent researchers on request since November 2010. 16 Furthermore, the EMA began proactively publishing CSRs submitted as part of marketing-authorisation applications for human medicines in 2016 and, in a second phase, plan to release deidentified individual patient data. 17 Recently, the FDA has implemented a pilot study to trial the release of CSRs, 18 and some pharmaceutical companies allow researchers to potentially access CSRs and individual patient data from their clinical trials (https://restoringtrials.
org/insitutions-offering-data-access/).
| CONCLUSIONS
Oseltamivir appears to play a causal role in the development of psychiatric AEs; however, the absolute risk is small. Clinical study reports provide a much richer database of information on AEs compared to other sources, including publications. Our methods can be used to fully utilise this information and provide additional insights into the unintended effects of pharmaceutical interventions. This has great relevance to future new drugs and their evaluation, especially for important early warnings of AEs.
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